Project Grant R01CA306993
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $667K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
- The National Cancer Institute awarded The Washington University $641,419 on May 7, 2026, to fund clinical translation of a Meitner-Auger positron emission tomography (PET) theranostic agent for metastatic castrate-resistant prostate cancer (MCRPC), under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The work investigates first-in-man clinical imaging of a stable bromine-77 ligand, [77Br]Br-WC-DZ, that targets PARP1, an abundant genome-associated target in cancer cells. The...
- The National Cancer Institute awarded The Washington University $637,394 on August 5, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop positron emission tomography imaging using a radiotracer (64Cu-DOTA-ECL1I) that quantifies C-C motif chemokine receptor 2 (CCR2) expression in head and neck squamous cell carcinoma patients. The project will establish CCR2-PET as a prognostic biomarker to predict tumor activity, disease recurrence, and response to...
- The National Cancer Institute awarded The Washington University $623,616 on July 10, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to support development of PET imaging methods for detecting and quantifying CD163+ tumor-associated macrophages in head and neck cancer. The research addresses the role of tumor-associated macrophages (TAMs) in the tumor microenvironment, which coordinate angiogenesis, extracellular matrix remodeling, cancer cell proliferation,...
- The National Cancer Institute awarded The Washington University $645,323 on July 10, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to conduct translational and clinical research on optimizing HER2 modulation in HER2-low breast tumors to enhance antibody-drug conjugate therapy. The research evaluates complementary biomarkers and therapeutic approaches to identify patients with HER2-low breast cancer who will respond to trastuzumab-deruxtecan (T-DXD) and to overcome...
- The National Cancer Institute awarded Washington University $562,550 on July 7, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop neoantigen-based spherical nucleic acid immunotherapeutics for triple negative breast cancer. The award funds development of a patient-specific nanoparticle immunotherapeutic, termed P-SNA, through an academic-industrial partnership between FlashPoint Therapeutics and the Gillanders Laboratory at Washington University School of Medicine. The...
- The National Cancer Institute awarded The Washington University $659,087 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support research targeting the NRF2 oxidative stress response pathway to sensitize head and neck squamous cell carcinoma (HNSCC) to immune checkpoint inhibitors. The research develops mechanistic understanding of how NRF2 pathway activation drives immune exclusion and resistance to anti-PD1 immunotherapy in HNSCC, which accounts for the sixth...
- The National Cancer Institute awarded The Washington University $399,829 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate ADAR1-regulated serine metabolism as a novel therapeutic target in triple-negative breast cancer. The funded research will elucidate the mechanisms underlying ADAR1-regulated serine metabolism and explore cancer therapeutic opportunities through this metabolic pathway. Washington University will conduct mechanistic studies in TNBC cell...
- The National Cancer Institute awarded the University of Washington $405,244 on August 13, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and optimize immunopixelseq, a cost-effective spatial immunosequencing platform for precision immuno-oncology research. Immunopixelseq uses 0.6-micrometer-resolution polony gel stamping to produce low-cost arrays compatible with standard Illumina short-read sequencing, enabling spatial co-profiling of whole-tissue...
- The National Cancer Institute awarded The Washington University $645,414 on June 18, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop integrin-targeted positron emission tomography imaging and therapeutics for predicting and treating radiation-induced pulmonary fibrosis in lung cancer patients. The project uses mouse models of radiation-induced pulmonary fibrosis to test two complementary approaches: non-invasive αvβ6 PET imaging to detect early...
- The National Cancer Institute awarded The Washington University $155,500 for research identifying and characterizing mutation-induced alternative splicing events in cancer using multi-omics data, with an award date of June 1, 2026 under the Cancer Biology Research program (CFDA 93.396). The project aims to discover mutation-induced alternative splicing events, understand their functional relevance, and identify neoantigens arising from these events to advance cancer immunotherapy. The research...